Hong Kong stocks of Innovative Pharmaceuticals continued to rise in the afternoon. Rongchang Biotech rose more than 16%, Junshi Biotech rose more than 7%, and Gloria Yingying rose by more than 5%, driving the innovative drug ETF Tianhong to rise 1.35% for the second day in a row. The cumulative increase this year was over 30%, ranking first among ETFs in the industry. Biomedical ETFs rose more than 0.5%. According to the news, following the joint issuance of “Certain Measures to Support the High-Quality Development of Innovative Drugs” by the National Health Insurance Administration and the National Health Commission on July 1 to help the development of innovative drugs, the State Drug Administration recently released ten measures to support the innovation and development of high-end medical devices. The focus is still on supporting innovative high-end medical devices. Tianhong and Linked Fund, an exclusive product in the market, is the only ETF in the market that tracks the Hang Seng Shanghai, Shenzhen, and Hong Kong Innovative Drug Selection 50 Index. It has achieved comprehensive coverage of A Shares+Hong Kong Shares, Innovative Pharmaceuticals+CXO, and combined with strict backtesting and optimization of quantitative indicators. Apart from the position opening period, all historical ranges have excess returns of about 3% per annum. Innovative Drug ETF Tianhong “sucked in gold” for 3 days in the past five trading days. The net flow rate for the past 5 days, 10 days, 20 days, and 60 days all ranked first in the category tracking Hong Kong A Innovative Drug. Biomedical ETFs and linked funds are the largest and most liquid products of the same standard. The increase since the beginning of the year is the highest. They track the biomedical index and distribute the pharmaceutical sector in a balanced manner, covering segments such as innovative drugs, vaccines, and blood products.

Hong Kong stocks of Innovative Pharmaceuticals continued to rise in the afternoon. Rongchang Biotech rose more than 16%, Junshi Biotech rose more than 7%, and Gloria Yingying rose by more than 5%, driving the innovative drug ETF Tianhong to rise 1.35% for the second day in a row. The cumulative increase this year was over 30%, ranking first among ETFs in the industry. Biomedical ETFs rose more than 0.5%. According to the news, following the joint issuance of “Certain Measures to Support the High-Quality Development of Innovative Drugs” by the National Health Insurance Administration and the National Health Commission on July 1 to help the development of innovative drugs, the State Drug Administration recently released ten measures to support the innovation and development of high-end medical devices. The focus is still on supporting innovative high-end medical devices. Tianhong and Linked Fund, an exclusive product in the market, is the only ETF in the market that tracks the Hang Seng Shanghai, Shenzhen, and Hong Kong Innovative Drug Selection 50 Index. It has achieved comprehensive coverage of A Shares+Hong Kong Shares, Innovative Pharmaceuticals+CXO, and combined with strict backtesting and optimization of quantitative indicators. Apart from the position opening period, all historical ranges have excess returns of about 3% per annum. Innovative Drug ETF Tianhong “sucked in gold” for 3 days in the past five trading days. The net flow rate for the past 5 days, 10 days, 20 days, and 60 days all ranked first in the category tracking Hong Kong A Innovative Drug. Biomedical ETFs and linked funds are the largest and most liquid products of the same standard. The increase since the beginning of the year is the highest. They track the biomedical index and distribute the pharmaceutical sector in a balanced manner, covering segments such as innovative drugs, vaccines, and blood products.